Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.70 |
| ▸ | MAOB | P27338 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | SDHA | P31040 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 9/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17032468 | 0.93 | MAOA (0.66) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL23992001 | 0.91 | MAOA (0.65) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL17034020 | 0.91 | MAOA (0.65) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL17034013 | 0.88 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL17039428 | 0.88 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL17032466 | 0.87 | MAOA (0.63) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL17034000 | 0.83 | MAOB (0.51) | MAOAMAOBLMNAPTGS1CALML3 | |
| Delpazolid SCHEMBL14354106 | 0.83 | MAOA (0.77) | MAOAMAOBLMNAPTGS1CALML3 | |
| Delpazolid SCHEMBL11969210 | 0.83 | MAOA (0.77) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL23992163 | 0.83 | MAOB (0.67) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107923-B1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2021-11-03 | — | — | EP | disclosed |
| US-9382276-B2 | Water-soluble O-carbonyl phosphoramidate prodrugs for therapeutic administration | MICURX PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015127316-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | MICURX PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150239922-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | SHANGHAI MICURX PHARMACEUTICAL CO. LTD. (CN) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239922-A1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | DPYD, SI, NUDT1 | MAOA 2019/4885MAOB 1186/4885LMNA 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.